{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:03:17Z","timestamp":1792623797235,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T00:00:00Z","timestamp":1623283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T00:00:00Z","timestamp":1623283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The purpose of this study was to report the incidence of elevated intraocular pressure (IOP) after intravitreal injection (IVI) of anti-vascular endothelial growth factor (VEGF) in Japanese patients with age-related macular degeneration (AMD). A retrospective study of chart review of patients who underwent\u2009\u2265\u200910 intravitreal anti-VEGF injections between April 2009 and December 2019 was conducted. Elevated IOP was defined as IOP\u2009\u2265\u200925\u00a0mmHg at one visit. Cases with elevated IOP resulting from IVI were identified. Furthermore, the association between elevated IOP and some parameters, as the risk factors that influence elevated IOP, was investigated. A total of 402 eyes of 370 patients were included in this study. Twenty-eight eyes of 26 patients (7.0%) were identified as cases with elevated IOP after IVI. The mean time of elevation after baseline was 50.6\u2009\u00b1\u200926.5\u00a0months. History of glaucoma (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.021; odds ratio, 5.85), treatment modality (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.019; odds ratio, 6.32), and total number of injections (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.003; odds ratio, 1.03) were significantly associated with elevated IOP. A late complication of elevated IOP is associated with IVI in patients with AMD. Particularly, history of glaucoma and treat and extend regimen with frequent injections were found to be risk factors of elevated IOP.\n                  <\/jats:p>","DOI":"10.1038\/s41598-021-91832-w","type":"journal-article","created":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T06:04:33Z","timestamp":1623305073000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Incidence of elevated intraocular pressure after intravitreal injection in Japanese patients with age-related macular degeneration"],"prefix":"10.1038","volume":"11","author":[{"given":"Maiko","family":"Maruyama-Inoue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaheeda","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Kitajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoko","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arisa","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Kadonosono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,10]]},"reference":[{"key":"91832_CR1","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/0039-6257(88)90052-5","volume":"32","author":"NM Bressler","year":"1988","unstructured":"Bressler, N. M., Bressler, S. B. & Fine, S. L. Age-related macular degeneration. Surv. Ophthalmol. 32, 375\u2013413 (1988).","journal-title":"Surv. Ophthalmol."},{"key":"91832_CR2","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1001\/archopht.121.1.113","volume":"121","author":"NM Bressler","year":"2003","unstructured":"Bressler, N. M. et al. Potential public health impact of age-related eye disease study results: AREDS report no. 11. Arch. Ophthalmol. 121, 1621\u20131624 (2003).","journal-title":"Arch. Ophthalmol."},{"key":"91832_CR3","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1136\/bjo.85.10.1153","volume":"85","author":"Y Oshima","year":"2001","unstructured":"Oshima, Y. et al. Prevalence of age related maculopathy in a representative Japanese population: the Hisayama study. Br. J. Ophthalmol. 85, 1153\u20131157 (2001).","journal-title":"Br. J. Ophthalmol."},{"key":"91832_CR4","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/S0002-9394(14)76661-9","volume":"85","author":"MM Kini","year":"1978","unstructured":"Kini, M. M. et al. Prevalence of senile cataract, diabetic retinopathy, senile macular degeneration, and open-angle glaucoma in the Framingham eye study. Am. J. Ophthalmol. 85, 28\u201334 (1978).","journal-title":"Am. J. Ophthalmol."},{"key":"91832_CR5","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1016\/S0161-6420(95)30846-9","volume":"102","author":"P Mitchell","year":"1995","unstructured":"Mitchell, P., Smith, W., Attebo, K. & Wang, J. J. Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study. Ophthalmology 102, 1450\u20131460 (1995).","journal-title":"Ophthalmology"},{"key":"91832_CR6","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1097\/IAE.0b013e3181e7976b","volume":"30","author":"KB Freund","year":"2010","unstructured":"Freund, K. B., Zweifel, S. A. & Engelbert, M. Do we need a new classification for choroidal neovascularization in age-related macular degeneration? Retina 30, 1333\u20131349 (2010).","journal-title":"Retina"},{"key":"91832_CR7","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.ajo.2014.07.006","volume":"158","author":"JJ Jung","year":"2014","unstructured":"Jung, J. J. et al. The incidence of neovascular subtypes in newly diagnosed neovascular age-related macular degeneration. Am. J. Ophthalmol. 158, 769-779.e762 (2014).","journal-title":"Am. J. Ophthalmol."},{"key":"91832_CR8","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld, P. J. et al. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 355, 1419\u20131431 (2006).","journal-title":"N. Engl. J. Med."},{"key":"91832_CR9","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier, J. S. et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119, 2537\u20132548 (2012).","journal-title":"Ophthalmology"},{"key":"91832_CR10","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.ajo.2007.01.052","volume":"143","author":"RE Frenkel","year":"2007","unstructured":"Frenkel, R. E., Mani, L., Toler, A. R. & Frenkel, M. P. Intraocular pressure effects of pegaptanib (Macugen) injections in patients with and without glaucoma. Am. J. Ophthalmol. 143, 1034\u20131035 (2007).","journal-title":"Am. J. Ophthalmol."},{"key":"91832_CR11","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1136\/bjo.2010.180729","volume":"95","author":"TJ Good","year":"2011","unstructured":"Good, T. J., Kimura, A. E., Mandava, N. & Kahook, M. Y. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br. J. Ophthalmol. 95, 1111\u20131114 (2011).","journal-title":"Br. J. Ophthalmol."},{"key":"91832_CR12","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.ophtha.2011.08.011","volume":"119","author":"QV Hoang","year":"2012","unstructured":"Hoang, Q. V. et al. Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections. Ophthalmology 119, 321\u2013326 (2012).","journal-title":"Ophthalmology"},{"key":"91832_CR13","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1089\/jop.2009.0076","volume":"26","author":"RA Adelman","year":"2010","unstructured":"Adelman, R. A., Zheng, Q. & Mayer, H. R. Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections. J. Ocul. Pharmacol. Ther. 26, 105\u2013110 (2010).","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"91832_CR14","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1097\/IAE.0b013e318217ffde","volume":"31","author":"DY Choi","year":"2011","unstructured":"Choi, D. Y. et al. Sustained elevated intraocular pressures after intravitreal injection of bevacizumab, ranibizumab, and pegaptanib. Retina 31, 1028\u20131035 (2011).","journal-title":"Retina"},{"key":"91832_CR15","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1007\/s00417-012-1981-0","volume":"250","author":"N Mathalone","year":"2012","unstructured":"Mathalone, N. et al. Sustained elevation of intraocular pressure after intravitreal injections of bevacizumab in eyes with neovascular age-related macular degeneration. Graefes Arch. Clin. Exp. Ophthalmol. 250, 1435\u20131440 (2012).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"91832_CR16","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jcjo.2014.11.004","volume":"50","author":"E Agard","year":"2015","unstructured":"Agard, E. et al. Repeated intravitreal anti-vascular endothelial growth factor injections can induce iatrogenic ocular hypertension, especially in patients with open-angle glaucoma. Can. J. Ophthalmol. 50, 127\u2013131 (2015).","journal-title":"Can. J. Ophthalmol."},{"key":"91832_CR17","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1016\/j.ajo.2014.02.035","volume":"157","author":"YJ Kim","year":"2014","unstructured":"Kim, Y. J. et al. Long-term effects of multiple intravitreal antivascular endothelial growth factor injections on intraocular pressure. Am. J. Ophthalmol. 157, 1266-1271.e1261 (2014).","journal-title":"Am. J. Ophthalmol."},{"key":"91832_CR18","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1097\/IAE.0b013e31823f0c95","volume":"32","author":"SJ Wehrli","year":"2012","unstructured":"Wehrli, S. J. et al. A lack of delayed intraocular pressure elevation in patients treated with intravitreal injection of bevacizumab and ranibizumab. Retina 32, 1295\u20131301 (2012).","journal-title":"Retina"},{"key":"91832_CR19","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1097\/IAE.0000000000000520","volume":"35","author":"VS Dedania","year":"2015","unstructured":"Dedania, V. S. & Bakri, S. J. Sustained elevation of intraocular pressure after intravitreal anti-VEGF agents: what is the evidence? Retina 35, 841\u2013858 (2015).","journal-title":"Retina"},{"key":"91832_CR20","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1097\/IAE.0b013e31816c6868","volume":"28","author":"SJ Bakri","year":"2008","unstructured":"Bakri, S. J. & Ekdawi, N. S. Intravitreal silicone oil droplets after intravitreal drug injections. Retina 28, 996\u20131001 (2008).","journal-title":"Retina"},{"key":"91832_CR21","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1097\/IAE.0b013e3181d50cea","volume":"30","author":"MY Kahook","year":"2010","unstructured":"Kahook, M. Y. et al. High-molecular-weight aggregates in repackaged bevacizumab. Retina 30, 887\u2013892 (2010).","journal-title":"Retina"},{"key":"91832_CR22","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1167\/iovs.10-6431","volume":"52","author":"L Liu","year":"2011","unstructured":"Liu, L. et al. Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibizumab: effects of long-term storage and product mishandling. Investig. Ophthalmol. Vis. Sci. 52, 1023\u20131034 (2011).","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"91832_CR23","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1159\/000346397","volume":"229","author":"MN Menke","year":"2013","unstructured":"Menke, M. N., Salam, A., Framme, C. & Wolf, S. Long-term intraocular pressure changes in patients with neovascular age-related macular degeneration treated with ranibizumab. Ophthalmologica 229, 168\u2013172 (2013).","journal-title":"Ophthalmologica"},{"key":"91832_CR24","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1097\/IJG.0000000000000173","volume":"25","author":"RG Morshedi","year":"2016","unstructured":"Morshedi, R. G., Ricca, A. M. & Wirostko, B. M. Ocular hypertension following intravitreal antivascular endothelial growth factor therapy: review of the literature and possible role of nitric oxide. J. Glaucoma 25, 291\u2013300 (2016).","journal-title":"J. Glaucoma"},{"key":"91832_CR25","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3928\/15428877-20090430-12","volume":"40","author":"MY Kahook","year":"2009","unstructured":"Kahook, M. Y. et al. Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections. Ophthalmic Surg. Lasers Imaging 40, 293\u2013295 (2009).","journal-title":"Ophthalmic Surg. Lasers Imaging"},{"key":"91832_CR26","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/IJG.0b013e31820d7d19","volume":"21","author":"JJ Tseng","year":"2012","unstructured":"Tseng, J. J. et al. Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. J. Glaucoma 21, 241\u2013247 (2012).","journal-title":"J. Glaucoma"},{"key":"91832_CR27","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1167\/iovs.16-20786","volume":"58","author":"JC Wen","year":"2017","unstructured":"Wen, J. C. et al. Intravitreal anti-VEGF injections reduce aqueous outflow facility in patients with neovascular age-related macular degeneration. Investig. Ophthalmol. Vis. Sci. 58, 1893\u20131898 (2017).","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"91832_CR28","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1167\/iovs.12-10260","volume":"54","author":"L Xu","year":"2013","unstructured":"Xu, L. et al. Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach. Investig. Ophthalmol. Vis. Sci. 54, 1616\u20131624 (2013).","journal-title":"Investig. Ophthalmol. Vis. Sci."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-91832-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-91832-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-91832-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T04:30:45Z","timestamp":1670041845000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-91832-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,10]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["91832"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-91832-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,10]]},"assertion":[{"value":"24 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12246"}}